Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MART-1 TCR-transduced autologous T-cell therapy for heavily pretreated metastatic melanoma
NL-OMON28054Recruiting
- Sponsor
- Netherlands Cancer Institute
- Start
- Apr 2012
- Modality
- TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Countries
- 1
01
Overview
Open-label trial of autologous MART-1-specific TCR-transduced T cells in melanoma, sponsored by Netherlands Cancer Institute. Primary endpoints: Safety and Objective response rate. Started Apr 2012; status: recruiting.
02
Drugs
autologous MART-1-specific TCR-transduced T cells
03
Conditions
melanoma
Beyond the preview
Go deeper on NL-OMON28054.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON28054.